The company announced the results during trading hours today, 24 April 2008.
Meanwhile, the BSE Sensex was up 9.97 points, or 0.06%, to 16,708.01, as some Asian shares got a lift after a stamp duty cut to slash dealing costs gave the flagging Shanghai index in China a boost, while a modest dollar rebound supported exporters.
On BSE, 73,880 shares were traded in the counter. The scrip had an average daily volume of 55,855 shares in the past one quarter.
The stock hit a high of Rs 347 and a low of Rs 335 so far during the day. The stock had a 52-week high of Rs 383 on 19 December 2007 and a 52-week low of Rs 231.25 on 21 August 2007.
The mid-cap scrip had outperformed the market over the past one month till 23 April 2008, gaining 11.21% compared to the Sensex`s return of 2.96%. It had also outperformed the market in the past one quarter, gaining 17% compared to Sensex`s decline of 3.04%.
The company`s current equity is Rs 41.80 crore. Face value per share is Rs 2.
The current price of Rs 341 discounts its Q3 December 2007 EPS of Rs 14.13, by a PE multiple of 24.13.
Nicholas Piramal India`s net profit rose 60.12% to Rs 301.48 crore on 18.18% growth in total income to Rs 1,938.07 crore on FY 2008 over FY 2007.
On 15 April 2008, Nicholas Piramal signed an agreement with Khandelwal Laboratories for the purchase of its anti-spasmodic Anafortan and antibiotic CEFI brands for a total consideration of Rs 116 crore.
In January 2008, the company acquired pharmaceuticals business of Healthline, Bangalore for a consideration of Rs 15 crore.
Nicholas Piramal India is one among the top ten pharmaceutical contract-manufacturing firms in the world.